$154 Million is the total value of CAXTON CORP's 69 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SVRA | New | SAVARA INC | $11,965,000 | – | 5,752,215 | +100.0% | 7.77% | – |
| LUXA | New | LUX HEALTH TECH ACQUISITION | $2,054,000 | – | 200,000 | +100.0% | 1.33% | – |
| AACU | New | ARES ACQUISITION CORPORATIONunit 99/99/9999 | $1,420,000 | – | 142,000 | +100.0% | 0.92% | – |
| MRAC | New | MARQUEE RAINE ACQUISITION CO | $1,042,000 | – | 105,500 | +100.0% | 0.68% | – |
| FLAC | New | FRAZIER LIFESCIENCES ACQU CO | $637,000 | – | 64,000 | +100.0% | 0.41% | – |
| SSAAU | New | SCIENCE STRATEGIC ACQ ALPHAunit 01/20/2026 | $616,000 | – | 62,000 | +100.0% | 0.40% | – |
| ONCS | New | ONCOSEC MED INC | $553,000 | – | 115,866 | +100.0% | 0.36% | – |
| GIGGU | New | GIGCAPITAL4 INCunit 99/99/9999 | $444,000 | – | 45,000 | +100.0% | 0.29% | – |
| SWBKU | New | SWITCHBACK II CORPORATIONunit 99/99/9999 | $397,000 | – | 39,000 | +100.0% | 0.26% | – |
| SRNGU | New | SOARING EAGLE ACQUISITION COunit 02/23/2026 | $364,000 | – | 36,000 | +100.0% | 0.24% | – |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $351,000 | – | 29,552 | +100.0% | 0.23% | – |
| BOASU | New | BOA ACQUISITION CORPunit 99/99/9999 | $338,000 | – | 34,070 | +100.0% | 0.22% | – |
| GMIIU | New | GORES METROPOULOS II INCunit 01/31/2028 | $323,000 | – | 32,000 | +100.0% | 0.21% | – |
| SVFA | New | SVF INVESTMENT CORP | $285,000 | – | 27,900 | +100.0% | 0.18% | – |
| FTOC | New | FTAC OLYMPUS ACQUISITION COR | $264,000 | – | 25,000 | +100.0% | 0.17% | – |
| HEC | New | HUDSON EXECUTIVE INVT CORP | $248,000 | – | 25,000 | +100.0% | 0.16% | – |
| ISOSU | New | ISOS ACQUISITION CORPORATIONunit 99/99/9999 | $239,000 | – | 24,000 | +100.0% | 0.16% | – |
| PV | New | PRIMAVERA CAPITAL ACQUIST CO | $235,000 | – | 24,000 | +100.0% | 0.15% | – |
| PICCU | New | PIVOTAL INVESTMENT CORP IIIunit 01/28/2028 | $168,000 | – | 16,800 | +100.0% | 0.11% | – |
| SPRQ | New | SPARTAN ACQUISITION CORP II | $115,000 | – | 11,000 | +100.0% | 0.08% | – |
| VGAC | New | VG ACQUISITION CORP | $112,000 | – | 11,000 | +100.0% | 0.07% | – |
| DGNR | New | DRAGONEER GROWTH OPPORTUN CO | $112,000 | – | 11,000 | +100.0% | 0.07% | – |
| RTP | New | REINVENT TECHNOLOGY PARTNERScl a | $112,000 | – | 11,000 | +100.0% | 0.07% | – |
| NGAC | New | NEXTGEN ACQUISITION CORPcl a | $109,000 | – | 11,000 | +100.0% | 0.07% | – |
| RMGCU | New | RMG ACQUISITION CORP IIIunit 02/08/2026 | $109,000 | – | 11,000 | +100.0% | 0.07% | – |
| AJAXWS | New | AJAX I*w exp 10/27/202 | $106,000 | – | 62,500 | +100.0% | 0.07% | – |
| LUXAW | New | LUX HEALTH TECH ACQUISITION*w exp 11/30/202 | $99,000 | – | 66,666 | +100.0% | 0.06% | – |
| MRACW | New | MARQUEE RAINE ACQUISITION CO*w exp 12/01/202 | $33,000 | – | 26,375 | +100.0% | 0.02% | – |
| FLACW | New | FRAZIER LIFESCIENCES ACQU CO*w exp 11/30/202 | $19,000 | – | 21,333 | +100.0% | 0.01% | – |
| PVWS | New | PRIMAVERA CAPITAL ACQUIST CO*w exp 01/19/202 | $10,000 | – | 12,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.